JP Morgan Chase
TBIO

JP Morgan Chase’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

JP Morgan Chase’s Portfolio TBIO Stock Details TBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31
Closed -$113 – 7766
2024
Q2 		$113 Buy
31
+1
+3% +$5 ﹤0.01% 6867
2024
Q1 		$234 Buy
30
+2
+7% +$15 ﹤0.01% 6790
2023
Q4 		$203 Hold
28
– – ﹤0.01% 7048
2023
Q3 		$530 Hold
28
– – ﹤0.01% 6717
2023
Q2 		$806 Hold
28
– – ﹤0.01% 6487
2023
Q1 		$2K Hold
28
– – ﹤0.01% 6455
2022
Q4 		$1K Sell
28
-72
-72% -$1.96K ﹤0.01% 6463
2022
Q3 		$3K Buy
100
+29
+41% +$1.02K ﹤0.01% 6209
2022
Q2 		$2K Sell
71
-360
-84% -$24.9K ﹤0.01% 6316
2022
Q1 		$42K Buy
431
+122
+39% +$18.5K ﹤0.01% 5863
2021
Q4 		$60K Buy
309
+144
+87% +$22.4K ﹤0.01% 5880
2021
Q3 		$33K Buy
+165
New +$41.9K ﹤0.01% 5939

Other funds holding TBIO

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

JP Morgan Chase's TBIO Position: Q3 2024 in Review

JP Morgan Chase sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q3 2024, closing a stake of 31 shares — an estimated $113 sold.

JP Morgan Chase first reported a position in TBIO in Q3 2021 and held it in 12 quarters. The position peaked at $60K in Q4 2021. 1 fund tracked by Wall St. Rank holds TBIO as of Q3 2024.

  • JP Morgan Chase reported no remaining Telesis Bio, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • JP Morgan Chase sold 31 Telesis Bio, Inc. Common Stock shares in Q3 2024, an estimated $113.
  • JP Morgan Chase first reported a position in Telesis Bio, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
  • JP Morgan Chase's Telesis Bio, Inc. Common Stock position peaked at $60K in Q4 2021.
  • 1 fund tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q3 2024.

Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.